Clinical Trial: Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07675174) titled 'Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT' on June 23.

Brief Summary: Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies undergoing an RIC allogeneic PBSC transplant from a 5/6 or 6/6 sibling or 7/8 or 8/8 matched unrelated donor.

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: GVHD - Graft-Versus-Host Disease

Intervention: DRUG: Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD

Interventional, non-randomized, open-label, ph...